No Clinically Significant Interaction Between Pregabalin and Warfarin
Pregabalin does not interact with warfarin and requires no special INR monitoring or warfarin dose adjustment beyond standard care. The FDA label for pregabalin (Lyrica) explicitly states that pregabalin undergoes negligible metabolism (<2%), does not bind to plasma proteins, and is predominantly excreted unchanged in the urine, making pharmacokinetic drug interactions highly unlikely 1.
Evidence Supporting No Interaction
The mechanism-based evidence is clear:
Pregabalin's pharmacokinetic profile eliminates interaction potential: It is not metabolized by cytochrome P450 enzymes, does not induce or inhibit these enzymes, and does not displace drugs from protein binding sites 1, 2
Direct research confirmation: A 2025 study specifically evaluated pregabalin with factor Xa inhibitors and found that pregabalin (dosed to 2 × 300 mg/d at steady-state) did not affect the exposure of any anticoagulant tested 3. While this study focused on direct oral anticoagulants rather than warfarin, the mechanism confirms pregabalin's lack of pharmacokinetic interference.
No documented interactions in clinical practice: The FDA label notes that pregabalin showed no pharmacokinetic interactions with multiple antiepileptic drugs, and "important pharmacokinetic interactions would not be expected to occur" with commonly used medications 1
Clinical Management
Continue standard INR monitoring per warfarin indication without modification when initiating pregabalin. The target INR remains 2.0-3.0 for most indications 4, and this should not change with pregabalin co-administration.
Important Caveat
While there is no pharmacokinetic interaction, pregabalin can cause additive CNS effects (cognitive impairment, sedation, dizziness) when combined with other CNS depressants 1. This does not affect anticoagulation but may increase fall risk, which is relevant for bleeding risk assessment in anticoagulated patients.
Contrast with Other Antiepileptics
This lack of interaction sharply contrasts with carbamazepine, which is a potent CYP450 inducer that reduces warfarin efficacy significantly (requiring ~50% warfarin dose increases) 5, 3. Pregabalin's clean pharmacokinetic profile makes it a safer choice when anticoagulation stability is a concern.